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Reports have shown increased systemic levels of endothelins during 
coronary artery bypass grafting in human beings. It was not known whether 
increased endothelin levels during coronary artery bypass grafting reflect a 
general systemic response to the surgical procedure or increased myocar- 
dial production of endotheiins in response to ischemia and reperfusion. We 
therefore measured endothelin levels in the right atrium and proximal 
aorta of 15 patients undergoing coronary artery bypass grafting for anginal 
syndrome immediately before aortic crossclamping and again after cessa- 
tion of cardiopulmonary bypass. In five patients, we also measured 
coronary sinus levels of endothelins during cardiopulmonary bypass circu- 
lation. We found that endothelin levels were elevated throughout the 
surgical procedure. Right atrial endothelin levels were significantly ele- 
vated after cessation of cardiopulmonary bypass circulation with respect to 
values immediately before aortic crossclamping (11.1 -- 3.1 vs 14.2 -+ 3.7 
pg/ml, p = 0.008), whereas endothelin levels in the proximal aorta did not 
rise significantly (10.5 -- 2.3 vs 11.6 -- 2.4 pg/ml, p > 0.5). Coronary sinus 
endothelin levels tended to decline temporarily during cardiopulmonary 
bypass circulation (11.1 -- 2.1 pg/ml before aortic crossclamping, 7.9 -- 1.9 
1 minute after release of aortic crossclamp, and 9.9 +- 2.1 pg/ml after 
release of partial aortic crossclamping, p = 0.06). We conclude that the rise 
in right atrial endothelin levels during coronary artery bypass grafting 
reflects systemic production and secretion of endothelins, probably by 
vasculature or organs distal to the proximal aorta, and is not the result of 
increased myocardial production and secretion of endothelins. (J Thorac 
Cardiovasc Surg 1996;112:531-6) 
T he endothelin family, known for its potent vaso- constrictive activity, ~consists of three structurally 
and pharmacologically distinct 21-amino acid 
isopeptides, ET-1, ET-2, and ET-3, each produced 
by a different gene. 2 Although endothelins were 
thought o be produced solely by endothelial cells, 
they have been shown to be produced by other cell 
types, 3-8 inchading cardiac myocytes. 9 ET-1 is the 
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most abundant and biologically active of the endo- 
thelin isopeptides in the human heart. 1° 
During acute myocardial infarction, circulating 
endothelin levels consistently are increased, espe- 
cially when the clinical course is complicated by 
heart failure. In contrast, during other forms of 
myocardial ischemia, such as stable and unstable 
angina, circulating endothelin levels remain unal- 
tered in most clinical studiesJ I In contrast o the 
relatively consistent results attained in human be- 
ings, endothelin levels in various animal models of 
myocardial ischemia and infarction have been re- 
ported to be increased, decreased or unchanged. 11 
Reports have shown increased systemic (arterial) 
levels of immunoreactive endothelins during coro- 
nary artery bypass grafting (CABG) in human be- 
ings. 12-15 Anesthesia nd surgical procedures may 
themselves elevate plasma levels of endothelins, 16' 17 
so increased endothelin levels during CABG in hu- 
man beings may reflect a general systemic response 
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Table I. Stages for blood sampling 
Surgical stage 
l 2 3 4 
Group A (n = 10) 
Aortic root X 
Right atrium X 
Group B (n = 5) 
Aortic root X 
Right atrium X 
Coronary sinus X 
X 
X 
X X X 
X X X 
X X 
Stage 1, Immediately before aortic rossclamping; Stage 2, 1 minute after 
release of aortic rossclamping; Stage 3, release of partial aortic ross- 
clamping; Stage 4, immediately after CPB. 
to the surgical procedure or myocardial production 
of endothelins in response to ischemia and reperfu- 
sion. lsq9 This study was undertaken (1) to charac- 
terize the kinetics of circulating endothelin levels 
during CABG and (2) to determine the contribution 
of the heart to changes in circulating endothelin 
levels during CABG in human beings. 
Methods 
Patients. The study population consisted of 15 patients 
undergoing CABG at Beilinson Medical Center on an 
elective basis for angina pectoris. Patients with chronic 
renal failure (serum creatinine >1.4 mg/dl), hepatic cir- 
rhosis, scleroderma, pulmonary hypertension, uncon- 
trolled hypertension, recent myocardial infarction, or se- 
vere congestive heart failure (ejection fraction <0.35 or 
New York Heart Association functional class III or IV) 
were excluded because these conditions have themselves 
been found to be associated with elevated plasma levels of 
endothelins. 2°-26 Patients were informed of the surgical 
procedure by the attending physician, after which they 
signed informed consent o undergo peration. 
Surgical protocol. Each patient was anesthetized with 
intravenous injections of midazolam (0.05 mg/kg body 
weight) and fentanyl (30 to 50 /xg/kg body weight). 
Muscular elaxation was obtained with pancuronium bro- 
mide (0.2 mg/kg body weight). Patients were mechanically 
ventilated (Narcomed 2B, N.A.D., Inc., Telford, Pa.) with 
adjustments in parameters to maintain normocapnia on 
frequent arterial blood gas measurements. The radial 
artery and internal jugular vein were cannulated for blood 
pressure and central venous pressure monitoring, respec- 
tively. Heart rate was monitored by surface electrocardi- 
ography. The mediastinum was exposed by a median 
sternotomy. Intravenous heparin (3 mg/kg body weight) 
was administered before cannulas were inserted for car- 
diopulmonary bypass (CPB), with repeated injections as 
necessary to maintain activated clotting time at longer 
than 400 seconds. Hypothermic (28 ° C) nonpulsatile CPB 
was established through a cannula in the ascending aorta 
and a cannula in the right atrium (two-stage cannula) for 
venous return. A disposable membrane oxygenator 
(Polystan, Copenhagen, Denmark) with polyvinyl chloride 
tubing was used with a roller pump. The extracorpeal 
circuit consisted of Hartman's olution, and the hemato- 
crit value was maintained at 25% -+ 1% during CPB. A 
small amount of pulmonary perfusion persisted and was 
returned to the heart-lung machine through aortic root 
aspiration. Grafting was performed uring a single period 
of aortic occlusion with cold (4 ° C) cardioplegic solution 
injected retrogradely into the coronary arteries through 
the aortic root and the coronary sinus. In group A (the 
first 10 patients), the cardioplegic solution consisted of 
Plasma-Lyte solution and 100 mg lidocaine, 40 mg papav- 
erine, 12 mEq potassium, and 500 mg methylpred- 
nisolone. In group B (five later patients), blood cardiople- 
gia was used. Induction blood cardioplegic solution 
(consisting of 400 mg lidocaine, 80 mg papaverine, 60 
mEq potassium, 500 mg methylprednisolone [Solu- 
Medrol] 2.5 gm glucose, 5gm magnesium ion, and 15 mEq 
sodium bicarbonate in 1000 ml saline solution) was given 
antegradely (aortic root) and retrogradely (coronary si- 
nus) simultaneously. The rate of induction of blood 
cardioplegia (blood/crystalloid dilution factor of 4:1) was 
200 to 250 ml/min, with a coronary sinus pressure limit of 
40 mm Hg. Every 20 to 30 minutes thereafter, cardiople- 
gia (400 mg lidocaine, 80 mg papaverine, 12 mEq potas- 
sium, 2.5 gm glucose, 5 gm magnesium ion and 15 mEq 
sodium bicarbonate) was given retrogradely. In both groups 
(A and B), the cardioplegic solution partially perfused the 
lungs and was collected outside the extracorpeal circuit. 
Blood samples. For all patients (groups A and B), 
arterial and mixed venous blood samples were drawn from 
indwelling cannulas in the ascending aorta (proximal to 
the connection of CPB circuit to aorta) and the right 
atrium, respectively. For patients in group B, blood sam- 
ples were also drawn from a cannula in the coronary sinus. 
The stages at which blood samples were drawn for each 
group are depicted in Table I. A 5 ml sample of blood was 
placed in a precooled tube containing ethylene diamine 
tetraacetate and 100 KIU aprotonin (Trasylol, Bayer AG, 
Leverkusen, Germany). All tubes were immersed in ice 
and later centrifuged at 3000 g for 15 minutes at 4 ° C. The 
supernatant from each tube was then stored in a vial at 
minus 70 ° C for subsequent biochemical analysis. 
ET assay. Plasma ET levels were determined with a 
commercial kit (Assay Kit 40-6026) purchased from Ni- 
chols Institute Diagnostics (The Netherlands). In short, 
preliminary extraction of ET was performed on silica C18 
(Nichols Institute) cartridges after acidification of plasma, 
followed by radioimmunoassay with an iodine 125 tracer 
and a polyclonal rabbit antibody. Endothelins were fur- 
ther separated by a second antibody solid-phase system 
and centrifugation. A standard curve was prepared and all 
results were read from the curve. The assay was per- 
formed by the same investigator (I. G.) in duplicate for 
each sample. The kit has a reported sensitivity of 2 pg/ml 
and specifities and cross-reactivities of 100% for ET-1, 
67% for ET-2, 84% for ET-3, 2.6% for big ET-1, 5.3% for 
big ET-2, and 0.2% for big ET-3. Mean value reported for 
normal control samples with this assay is 2.9 pg/ml. In our 
laboratory, we found mean values of 2.6 _+ 0.7 pg/ml for a 
group of 10 normal volunteers. 
Statistics. Results are presented as mean (_+ standard 
deviation). The Wilcoxon signed rank test was used to 
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Table II. Demographic, clinical, and procedural data 
Age X CPB 
No. Group (yr) Sex MI HTN D M (±in) (rnin ) Grafts 
1 A 60 M + - + 54 80 4 
2 A 67 F + + - 27 47 2 
3 A 69 M - - - 48 75 2 
4 A 66 F + + - 48 82 3 
5 A 70 F - - - 45 78 2 
6 A 65 M - - - 47 73 2 
7 A 46 M + + - 61 103 4 
8 A 61 F - - + 83 143 4 
9 A 65 F + - + 45 66 3 
10 A 61 M + - - 47 75 3 
11 B 72 F - + + 83 143 4 
12 B 62 M + - + 50 82 3 
13 B 47 M - - + 76 132 4 
14 B 59 M + + - 96 180 5 
15 B 69 M + + - 68 122 4 
MI, History of myocardial infarction; HTN, history of hypertension; DM, history of diabetes mellitus; X, aortic crossclamp time. 
compare ndothelin levels. All tests were two-tailed, andp 
values no greater than 0.05 were considered significant. 
Results 
The study population consisted of 15 patients, 
nine men and six women, ranging in age from 46 to 
72 years (mean +_ standard eviation 62.6 ± 7.6 
years). Demographic and clinical characteristics for 
each patient are presented in Table II, as are data 
concerning the surgical procedure. Endothelin lev- 
els were elevated throughout the surgical procedure 
with respect o normal values. As is apparent in Fig. 
1, right atrial endothelin levels were significantly 
higher immediately after cessation of CPB versus 
values before aortic crossclamping (n = 15, 11.1 _+ 
3.1 vs 14.2 ± 3.7 pg/ml, p = 0.008). This trend was 
seen in both groups (for group A [n = 10], 11.5 _+ 
2.1 vs 14.7 ± 4.2 pg/ml, p = 0.03; for group B [n = 
5], 10.4 ± 4.7 vs 13.2 _+ 2.7 pg/ml, p = 0.13). 
Endothelin levels in the proximal aorta, however, 
were not ,significantly higher immediately after ces- 
sation of CPB (group A [n = 10] 11.5 ± 2 vs 11.9 ± 
2.2 pg/ml, p > 0.5; group B [n = 5] 8.6 -+ 1.5 vs 10.9 
+ 2.8 pg/ml, p = 0.34; combined [n = 15] 10.5 _+ 2.3 
vs 11.6 _+ 2.4 pg/ml, p > 0.5). In addition, whereas 
right atrial endothelin levels were similar to proxi- 
mal aortic endothelin levels before aortic cross- 
clamping (n -- 15, 10.5 _+ 2.3 vs 11.1 _+ 3.1 pg/ml, 
p > 0.5), they were significantly higher after cessa- 
tion of CPB (n = 15, 11.6 ± 2.4 vs 14.2 _+ 3.7 pg/ml, 
p = 0.04 i, indicating increased secretion and pro- 
duction Of endothelins in vasculature or organs 
distal to the: proximal aorta. In the five patients 
belonging to group B, coronary sinus levels of 
endothelins obtained uring CPB tended to decline 
temporarily with ensuing recovery (11.1 ± 2.1 pg/ml 
before aortic crossclamping 7.9 ± 1.9 1 minute after 
release of aortic crossclamping, and 9.9 _+ 2.1 pg/ml 
after release of partial aortic crossclamping, p = 
0.06; Fig. 2). At the same times, endothelin levels in 
the proximal aorta tended to rise immediately after 
release of aortic crossclamping and then returned to 
precrossclamp values (8.6 ± 1.5, 12.5 _+ 3.5, and, 
10.2 ± 2.4 pg/ml, respectively, p = 0.06). 
Discussion 
Previous studies of ET levels during CABG. Pre- 
vious studies have reported increased arterial endo- 
thelin levels in the course of CABG in human 
beings. 12-15 Although Hynynen and coworkers 15 
proposed that elevated endothelin levels during 
CABG reflect surgical stress and catecholamine 
release, Knothe and colleagues 13found that arterial 
endothelin levels did not correlate with systemic 
hemodynamic or endocrinologic parameters (in- 
cluding catecholamine l vels). None of the studies 
examined whether the heart contributed to the 
elevation in circulating plasma endothelin levels. To 
this end, we measured arterial, mixed venous, and 
coronary sinus endothelin levels during CABG in 
human beings. Moreover, to avoid any effects of 
hemodynamic nstability on endothelin levels, we 
enrolled only patients with stable hemodynamic 
status before and during the surgical procedure (as 
reflected by monitored heart rate, blood pressure, 
urine output, and blood gas values). 
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Fig. 1. Mean right atrial and proximal aortic levels of 
endothelins (ET) in patients (groups A and B combined, 
n = 15) immediately before aortic rossclamping and after 
cessation of cardio-pulmonary b pass circulation. (See 
text for statistical nalysis.) 
Main finding of study. The main finding of this 
study was that circulating endothelin levels increase 
in the course of CABG. Right atrial endothelin 
levels were significantly elevated after cessation of 
CPB, compared with values immediately before 
aortic crossclamping. Endothelin levels in the prox- 
imal aorta did not rise significantly. Coronary sinus 
levels of endothelins measured in five patients also 
did not rise during CPB; rather, they tended to 
decline temporarily. We therefore conclude that the 
rises in right atrial endothelin levels reflect systemic 
production and secretion of endothelins, most prob- 
ably by vasculature or organs distal to the proximal 
aorta, and is not the result of increased myocardial 
production and secretion of endothelins. The trend 
toward transient increases in proximal aortic endo- 
thelin levels immediately after release of aortic 
crossclamping most probably reflects washout of 
blood that partially perfused the lungs and accumu- 
lated in the heart during cardioplegia. 
Our data demonstrate marked fluctuations in 
endothelin levels during CABG. Indeed, the dispar- 
ities among different studies to date regarding the 
effect of myocardial ischemia and reperfusion on 
circulating endothelin levels 11 may be partially ex- 
plained by temporal differences in drawing of blood 
samples and differences in the source of the blood 
samples (arterial, venous, coronary sinus). We chose 
to obtain baseline ndothelin levels for all patients 
immediately before aortic crossclamping (rather 
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Fig. 2. Mean right atrial, proximal aortic, and coronary 
sinus levels of endothelins (ET) in five patients of group B 
immediately before aortic crossclamping, 1 minute after 
release of aortic rossclamping, and after elease of partial 
aortic crossclamping. (See text for statistical nalysis.) 
than before operation) to preclude possible effects 
on circulating endothelin levels of anesthesia, me- 
chanical ventilation, and vascular injury during ve- 
nous and arterial manipulation. Indeed, it is known 
that anesthesia nd the surgical procedure them- 
selves increase plasma endothelin levels, l< 17 Simi- 
larly, we examined endothelin levels in all patients 
again immediately after cessation of CPB because 
previous studies showed that arterial endothelin 
levels are highest at this stage. 12' 13 As shown re- 
cently by Wang and coworkers 27 and previously 
shown by others, 11 endothelin levels rise only during 
the reperfusion period after experimental myocar- 
dial ischemia. For patients in group B, we therefore 
also measured coronary sinus levels of ET in two 
stages of CPB, representing different stages of the 
reperfusion period. 
Systemic versus local ET levels. Endothelins may 
be secreted into systemic irculation or abluminally 
to the interstitium. Indeed, it is claimed that ablu- 
minal secretion of endothelins i  predominant, and 
that the major effect of endothelins is exerted at the 
paracrine level. ~1'2s For example, Wang and co- 
workers 27 reported a slight increase in coronary 
venous endothelin levels during the reperfusion 
period in pigs subjected to 45 minutes of coronary 
artery ligation. This rise was minute, however, com- 
pared with the dramatic rise in tissue content of 
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endothelins in the ischemic myocardium. In con- 
trast, Hiramatsu and associates 29 recently showed 
that coronary sinus levels of endothelins are not 
altered during experimental CPB in lambs. In our 
study we measured only coronary sinus endothelin 
levels and not tissue levels, so we cannot determine 
unequivocally the effects of myocardial ischemia nd 
reperfusion during CABG on myocardial endothelin 
levels. Our finding that coronary sinus endothelin 
levels are not elevated in the course of CABG 
(rather, they tend to decline temporarily), however, 
indicates that even if there is increased myocardial 
endothelin production and secretion, this does not 
affect systemic endothelin levels. 
Implications regarding CABG. The clinical sig- 
nificance of elevated endothelin levels during 
CABG has yet to be determined. Although endo- 
thelins were thought to be merely amarker for stress 
(acute phase reactant), la'ao it is now reasonable to 
assume that they play an important role during 
CABG in light of the multitude of effects that they 
exert on the cardiovascular system. 1I In the acute 
phase, endothelins may affect recovery from car- 
dioplegic ischemia a9 by attenuating microvascular 
flow in the reperfused bed. 3° Because they are 
potent vasoconstrictors, 1 they may also be at least 
partially responsible for the phenomenon of acute 
hypertension in the immediate postoperative p riod 
after CABG. 31 Indeed, Boldt and colleagues 14re- 
cently showed that administration of angiotensin- 
converting enzyme inhibitors to patients undergoing 
heart operations reduces mean arterial pressure 
significantly during operation; this reduction occurs 
concomitantly with an attenuation of a rise in 
plasma endothelin levels. Moreover, the vasocon- 
strictive properties of endothelins may account for 
spasm of arterial grafts, thus compromising both 
acute blood flow and subsequent patency. 3a In the 
long run, the effects of endothelins as potent pro- 
motors of vascular smooth muscle proliferation 33-35 
and intimal hyperplasia fter vascular injury 36 may 
contribute to the process of venous and arterial graft 
stenosis. As mentioned previously the local effects of 
endothelins may be of greater importance than their 
systemic effects. Myocardial production and secre- 
tion of endothelins during CABG thus might also 
have profound acute and long-term effects. With the 
recent introduction of novel therapeutic strategies 
designed to attenuate ndothelin levels or activity 
(for example, endothelin-receptor antagonists37), it 
might be possible to prevent some of these short- 
and long-term complications. 
Although this study was not designed to compare 
cardioplegic protocols, our data suggests that both 
cardioplegic protocols are associated with similar 
circulating endothelin levels and with the same 
fluctuation trends in endothelin levels. Because of 
the small number of patients in each group, how- 
ever, further research is warranted to compare 
endothelin levels with different cardioplegic proto- 
cols. 
Conclusion. This study shows that systemic endo- 
thelin levels are elevated uring CABG and suggests 
that these changes reflect increased systemic, rather 
than myocardial, production and secretion of endo- 
thelins. Moreover, although myocardial endothelin 
levels may rise during CABG as a result of increased 
myocardial production and secretion, these changes 
are confined to the heart and may not have an effect 
on systemic endothelin levels. 
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